|
1
|
Rawla P, Sunkara T and Gaduputi V:
Epidemiology of pancreatic cancer: Global trends, etiology and risk
factors. World J Oncol. 10:10–27. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Tsai HJ and Chang JS: Environmental risk
factors of pancreatic cancer. J Clin Med. 8:14272019. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ilic M and Ilic I: Epidemiology of
pancreatic cancer. World J Gastroenterol. 22:9694–9705. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Cancer Statistics, . Cancer Information
Service, National Cancer Center, Japan (Vital Statistics of Japan,
Ministry of Health, Labour and Welfare). https://view.officeapps.live.com/op/view.aspx?src=https%3A%2F%2Fganjoho.jp%2Freg_stat%2Fstatistics%2Fdata%2Fdl%2Fexcel%2Fcancer_mortality(1958–2020).xls&wdOrigin=BROWSELINKMay
9–2022
|
|
5
|
Von Hoff DD, Ervin T, Arena FP, Chiorean
EG, Infante J, Moore M, Seay T, Tjulandin SA, Ma WW, Saleh MN, et
al: Increased survival in pancreatic cancer with nab-paclitaxel
plus gemcitabine. N Engl J Med. 369:1691–1703. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Tempero MA, Malafa MP, Al-Hawary M,
Behrman SW, Benson AB, Cardin DB, Chiorean EG, Chung V, Czito B,
Del Chiaro M, et al: Pancreatic adenocarcinoma, version 2.2021,
NCCN clinical practice guidelines in oncology. J Natl Compr Canc
Netw. 19:439–457. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ueno H, Ikeda M, Ueno M, Mizuno N, Ioka
TE, Omuro Y, Nakajima T and Furuse J: Phase I/II study of
nab-paclitaxel plus gemcitabine for chemotherapy-naive Japanese
patients with metastatic pancreatic cancer. Cancer Chemother
Pharmacol. 77:595–603. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Rosenberg IH: Sarcopenia: Origins and
clinical relevance. J Nutr. 127 (5 Suppl):990S–991S. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Fearon K, Strasser F, Anker SD, Bosaeus I,
Bruera E, Fainsinger RL, Jatoi A, Loprinzi C, MacDonald N,
Mantovani G, et al: Definition and classification of cancer
cachexia: An international consensus. Lancet Oncol. 12:489–495.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Bauer J, Morley JE, Schols AMWJ, Ferrucci
L, Cruz-Jentoft AJ, Dent E, Baracos VE, Crawford JA, Doehner W,
Heymsfield SB, et al: Sarcopenia: A time for action. An SCWD
position paper. J Cachexia Sarcopenia Muscle. 10:956–961. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Cruz-Jentoft AJ, Baeyens JP, Bauer JM,
Boirie Y, Cederholm T, Landi F, Martin FC, Michel JP, Rolland Y,
Schneider SM, et al: Sarcopenia: European consensus on definition
and diagnosis: Report of the European working group on sarcopenia
in older people. Age Ageing. 39:412–423. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Chen LK, Liu LK, Woo J, Assantachai P,
Auyeung TW, Bahyah KS, Chou MY, Chen LY, Hsu PS, Krairit O, et al:
Sarcopenia in Asia: Consensus report of the Asian working group for
sarcopenia. J Am Med Dir Assoc. 15:95–101. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Walowski CO, Braun W, Maisch MJ, Jensen B,
Peine S, Norman K, Müller MJ and Bosy-Westphal A: Reference values
for skeletal muscle mass-current concepts and methodological
considerations. Nutrients. 12:7552020. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
González Correa CH, Marulanda Mejía F,
Castaño González PA, Vidarte Claros JA and Castiblanco Arroyabe HD:
Bioelectrical impedance analysis and dual x-ray absorptiometry
agreement for skeletal muscle mass index evaluation in sarcopenia
diagnosis. Physiol Meas. 41:0640052020. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
McSharry V, Glennon K, Mullee A and
Brennan D: The impact of body composition on treatment in ovarian
cancer: A current insight. Expert Rev Clin Pharmacol. 14:1065–1074.
2021. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
McSharry V, Mullee A, McCann L, Rogers AC,
McKiernan M and Brennan DJ: The impact of sarcopenia and low muscle
attenuation on overall survival in epithelial ovarian cancer: A
systematic review and meta-analysis. Ann Surg Oncol. 27:3553–3564.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Sakamoto T, Yagyu T, Uchinaka E, Miyatani
K, Hanaki T, Kihara K, Matsunaga T, Yamamoto M, Tokuyasu N, Honjo S
and Fujiwara Y: Sarcopenia as a prognostic factor in patients with
recurrent pancreatic cancer: A retrospective study. World J Surg
Oncol. 18:2212020. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ubachs J, Ziemons J, Minis-Rutten IJG,
Kruitwagen RFPM, Kleijnen J, Lambrechts S, Olde Damink SWM, Rensen
SS and Van Gorp T: Sarcopenia and ovarian cancer survival: A
systematic review and meta-analysis. J Cachexia Sarcopenia Muscle.
10:1165–1174. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Yang M, Shen Y, Tan L and Li W: Prognostic
value of sarcopenia in lung cancer: A systematic review and
meta-analysis. Chest. 156:101–111. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ishida T, Makino T, Yamasaki M, Tanaka K,
Miyazaki Y, Takahashi T, Kurokawa Y, Motoori M, Kimura Y, Nakajima
K, et al: Impact of measurement of skeletal muscle mass on clinical
outcomes in patients with esophageal cancer undergoing
esophagectomy after neoadjuvant chemotherapy. Surgery.
166:1041–1047. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kim IH, Choi MH, Lee IS, Hong TH and Lee
MA: Clinical significance of skeletal muscle density and sarcopenia
in patients with pancreatic cancer undergoing first-line
chemotherapy: A retrospective observational study. BMC Cancer.
21:772021. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Shachar SS, Deal AM, Weinberg M, Nyrop KA,
Williams GR, Nishijima TF, Benbow JM and Muss HB: Skeletal muscle
measures as predictors of toxicity, hospitalization, and survival
in patients with metastatic breast cancer receiving taxane-based
chemotherapy. Clin Cancer Res. 23:658–665. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Sobin LH, Gospodarowicz MK and Wittekind
C: TNM classification of malignant tumours. 7th edition.
Chichester, West Sussex, UK: Wiley-Blackwell; 2010
|
|
24
|
Oken MM, Creech RH, Tormey DC, Horton J,
Davis TE, McFadden ET and Carbone PP: Toxicity and response
criteria of the eastern cooperative oncology group. Am J Clin
Oncol. 5:649–655. 1982. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Chien MY, Huang TY and Wu YT: Prevalence
of sarcopenia estimated using a bioelectrical impedance analysis
prediction equation in community-dwelling elderly people in Taiwan.
J Am Geriatr Soc. 56:1710–1715. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Body mass index-BMI. World Health
Organization, regional office for Europe, . https://www.who.int/data/gho/data/themes/topics/topic-details/GHO/body-mass-indexFebruary
13–2022
|
|
27
|
Imaoka H, Mizuno N, Hara K, Hijioka S,
Tajika M, Tanaka T, Ishihara M, Yogi T, Tsutsumi H, Fujiyoshi T, et
al: Evaluation of modified Glasgow prognostic score for pancreatic
cancer: A retrospective cohort study. Pancreas. 45:211–217. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Schwartz LH, Litière S, de Vries E, Ford
R, Gwyther S, Mandrekar S, Shankar L, Bogaerts J, Chen A, Dancey J,
et al: RECIST 1.1-update and clarification: From the RECIST
committee. Eur J Cancer. 62:132–137. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Common Terminology Criteria for Adverse
Events (CTCAE) Version 5, . Published: November 27. US Department
of Health and Human Services, National Institutes of Health,
National Cancer Institute;
|
|
30
|
Ozola Zalite I, Zykus R, Francisco
Gonzalez M, Saygili F, Pukitis A, Gaujoux S, Charnley RM and Lyadov
V: Influence of cachexia and sarcopenia on survival in pancreatic
ductal adenocarcinoma: A systematic review. Pancreatology.
15:19–24. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Begini P, Gigante E, Antonelli G,
Carbonetti F, Iannicelli E, Anania G, Imperatrice B, Pellicelli AM,
Fave GD and Marignani M: Sarcopenia predicts reduced survival in
patients with hepatocellular carcinoma at first diagnosis. Ann
Hepatol. 16:107–114. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Vergara-Fernandez O, Trejo-Avila M and
Salgado-Nesme N: Sarcopenia in patients with colorectal cancer: A
comprehensive review. World J Clin Cases. 8:1188–1202. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Zhang XM, Dou QL, Zeng Y, Yang Y, Cheng
ASK and Zhang WW: Sarcopenia as a predictor of mortality in women
with breast cancer: A meta-analysis and systematic review. BMC
Cancer. 20:1722020. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Bundred J, Kamarajah SK and Roberts KJ:
Body composition assessment and sarcopenia in patients with
pancreatic cancer: A systematic review and meta-analysis. HPB
(Oxford). 21:1603–1612. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Choi Y, Oh DY, Kim TY, Lee KH, Han SW, Im
SA, Kim TY and Bang YJ: Skeletal muscle depletion predicts the
prognosis of patients with advanced pancreatic cancer undergoing
palliative chemotherapy, independent of body mass index. PLoS One.
10:e01397492015. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Vashi P, Popiel B, Lammersfeld C and Gupta
D: Outcomes of systematic nutritional assessment and medical
nutrition therapy in pancreatic cancer. Pancreas. 44:750–755. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Lv Y, Ji ML, Feng QY, Zhu DX, Lin SB, Mao
YH, Xu YQ, Zheng P, He GD and Xu JM: Combined test of third lumbar
skeletal muscle index and prognostic nutrition index improve
prognosis prediction power in resected colorectal cancer liver
metastasis. Aging (Albany NY). 11:10301–10315. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
García-Luna PP, Parejo Campos J and
Pereira Cunill JL: Causes and impact of hyponutrition and cachexia
in the oncologic patient. Nutr Hosp. 21 (Suppl 3):S10–S16. 2006.(In
Spanish). PubMed/NCBI
|
|
39
|
Solheim TS, Laird BJA, Balstad TR, Stene
GB, Bye A, Johns N, Pettersen CH, Fallon M, Fayers P, Fearon K and
Kaasa S: A randomized phase II feasibility trial of a multimodal
intervention for the management of cachexia in lung and pancreatic
cancer. J Cachexia Sarcopenia Muscle. 8:778–788. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Proctor MJ, Morrison DS, Talwar D, Balmer
SM, O'Reilly DS, Foulis AK, Horgan PG and McMillan DC: An
inflammation-based prognostic score (mGPS) predicts cancer survival
independent of tumour site: A Glasgow inflammation outcome study.
Br J Cancer. 104:726–734. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Zhang H, Ren D, Jin X and Wu H: The
prognostic value of modified Glasgow prognostic score in pancreatic
cancer: A meta-analysis. Cancer Cell Int. 20:4622020. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Fu W, Wang K, Yan S, Wang X, Tang B, Chang
J, Wang R and Wu T: Prognostic significance of the modified Glasgow
prognostic score in patients with pancreatic cancer: A
meta-analysis. Dose Response. 18:15593258209420652020. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Lee HS, Kim SY, Chung MJ, Park JY, Bang S,
Park SW and Song SY: Skeletal muscle mass predicts poor prognosis
in patients with advanced pancreatic cancer undergoing second-line
FOLFIRINOX chemotherapy. Nutr Cancer. 71:1100–1107. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Park I, Choi SJ, Kim YS, Ahn HK, Hong J,
Sym SJ, Park J, Cho EK, Lee JH, Shin YJ and Shin DB: Prognostic
factors for risk stratification of patients with recurrent or
metastatic pancreatic adenocarcinoma who were treated with
gemcitabine-based chemotherapy. Cancer Res Treat. 48:1264–1273.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Antonio J, Kenyon M, Ellerbroek A, Carson
C, Burgess V, Tyler-Palmer D, Mike J, Roberts J, Angeli G and
Peacock C: Comparison of dual-energy X-ray absorptiometry (DXA)
versus a multi-frequency bioelectrical impedance (InBody 770)
device for body composition assessment after a 4-week hypoenergetic
diet. J Funct Morphol Kinesiol. 4:232019. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Jones DJ, Lal S, Strauss BJ, Todd C,
Pilling M and Burden ST: Measurement of muscle mass and sarcopenia
using anthropometry, bioelectrical impedance, and computed
tomography in surgical patients with colorectal malignancy:
Comparison of agreement between methods. Nutr Cancer. 72:1074–1083.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Looijaard WGPM, Stapel SN, Dekker IM,
Rusticus H, Remmelzwaal S, Girbes ARJ, Weijs PJM and Oudemans-van
Straaten HM: Identifying critically ill patients with low muscle
mass: Agreement between bioelectrical impedance analysis and
computed tomography. Clin Nutr. 39:1809–1817. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Chang MY, Park Y, Ha JW, Zhang HY and Lee
SH, Hong TH and Lee SH: Paraspinal lean muscle mass measurement
using spine MRI as a predictor of adjacent segment disease after
lumbar fusion: A propensity score-matched case-control analysis.
AJR Am J Roentgenol. 212:1310–1317. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Zhou S, Shang Q, Wang N, Li Q, Song A and
Luan Y: Rational design of a minimalist nanoplatform to maximize
immunotherapeutic efficacy: Four birds with one stone. J Control
Release. 328:617–630. 2020. View Article : Google Scholar : PubMed/NCBI
|
